EANS-Adhoc: Capital increase to accompany Curanum's follow-up financing

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

27.09.2012

In parallel with the follow-up financing for the borrower's note loan
which is shortly to be concluded, the Management and Supervisory
boards of Curanum AG have today passed a resolution to increase the
company's share capital through issuing up to 3,315,000 ordinary
bearer shares, each with a notional interest in the share capital of
EUR 1.00 per share. To this end, the approved capital is to be
completely utilized from currently EUR 39,192,000 to up to EUR
42,507,000 through granting subscription rights to all shareholders
against cash. With the capital increase, not only is the operating
business to be strengthened, but the company is also to be enabled to
implement its future concepts which are oriented to further earnings
improvement.

The new shares will be offered to shareholders in a 11.7:1 ratio, at
a subscription price of EUR 1.50 per share. The 405,102 treasury
shares owned by the company will not participate in the subscription
offer. The subscription offer will be published in the electronic
Federal Gazette prospectively on October 2, 2012. The subscription
period is set to run from October 4, 2012 until October 18, 2012. The
stock market listing and delivery of the new shares to shareholders
are planned to occur subsequently.

The new shares are fully dividend-entitled for the 2012 financial
year. The subscription offer is directed exclusively to existing
shareholders. There are no plans to organize subscription rights
trading. With the subscription offer, the right is also to be granted
exclusively to the company's shareholders to acquire by way of
oversubscription at the subscription price any new shares which have
not been subscribed for by other shareholders. Binding offers for
such oversubscriptions are to be submitted during the subscription
period. If the allocation of additional requested new shares to all
shareholders proves impossible due to high oversubscription demand,
the company will decide at its due discretion concerning the
allocation while complying with the principle of equal treatment. The
new shares are to be admitted to trading on the Regulated Market
(Prime Standard) on the Frankfurt Stock Exchange, without the
publication of a securities prospectus.

Further inquiry note:
Caroline Lutz
Leitung Unternehmensentwicklung
Tel.: +49(0)89/ 24 20 65-0
E-Mail: ir@curanum.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: CURANUM AG
Engelbertstraße 23-25
D-81241 München
phone: +49 (0)89 242065 51
FAX: +49 (0) 89 242065 10
mail: info@curanum.de
WWW: http://www.curanum.de
sector: Healthcare Providers
ISIN: DE0005240709
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Hamburg, Düsseldorf, Stuttgart, regulated
dealing: München, regulated dealing/prime standard: Frankfurt
language: English